. In vivo studies demonstrated that daily i.p. injections of FA led to profound regression of the COLO-205 tumors and prolong the lifespan. In these tumors, the levels of CDKN1A, CDKN1B and TP53 protein were increased and von willebrand factor (VWF) protein levels were decreased. These findings suggest that FA inhibits COLO-205 colon cancer growth through anticancer cell proliferation and anti-angiogenesis.
Results

Effects
by FA treatment, we conducted Trypan blue assays to examine the cell viability by treating the cell with FA for 6 days at a concentration of 10 μ M used in the studies of [3H]thymidine incorporation. The results showed that FA did not cause any significant cell death as compared with the cell treated with vehicle (0.02 ± 0.01% for FA-treated group vs. 0.03 ± 0.01% for vehicle-treated group). Since FA arrested the cell cycle of COLO-205 at the G0/G1 phase, we examined the effect of FA on the levels of G1 phase regulatory proteins in COLO-205. FA-induced increases in the levels of TP53, CDKN1A, and CDKN1B were observed at 12 h after FA treatment (Fig. 1C) . As shown in Fig. 1D , FA (0.1-10 μ M) concentration-dependently decreased the levels of CDK2 protein, increased the levels of CDKN1A, CDKN1B and TP53 protein, but not significantly affected the levels of cyclin A, D1, D3, and E, and CDK4 protein.
Up-regulation of TP53 contributes to FA-induced CDKN1A and CDKN1B up-regulations and G0/G1 arrest in COLO-205. To further investigate whether FA-induced increases in the levels of CDKN1A and CDKN1B protein and the G0/G1 arrest were regulated by TP53, the dominant negative TP53 cDNA (DN-TP53 cDNA), which is the mutant construct for DNA binding site of TP53 18 , was transfected into COLO-205 followed by FA treatment. As illustrated in Fig. 2A , pre-transfection with DN-TP53 cDNA abolished FA-induced increases in the levels of TP53, CDKN1A and CDKN1B protein. Moreover, pre-transfection with DN-TP53 cDNA also abolished the FA-induced G0/G1 arrest in COLO-205 (Fig. 2B ).
Signaling pathway involved in the FA-induced up-regulation of TP53 in COLO-205. We further investigated the signaling pathway involved in the FA-induced TP53 up-regulation in COLO-205. Since activation of the c-SRC/ERK 2/NFκ B-mediated pathway has been demonstrated to be involved in the FA-induced TP53 up-regulation and proliferation inhibition in HUVEC 17 , we examined whether activations in c-SRC and ERK are also involved in FA-induced up-regulations in the levels of TP53, CDKN1A, and CDKN1B protein in COLO-205. Treatment with FA (10 μ M) for 2 min increased in the levels of p-c-SRC and p-ERK1/2 protein in COLO-205 (Fig. 3A) , suggesting the involvement of c-SRC and ERK1/2 activation in FA-induced up-regulations in TP53, CDKN1A, and CDKN1B protein in COLO-205. Pre-treatment of COLO-205 with the c-SRC inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d] pyramidine (PP2, 200 nM), prevented FA-induced increases in the level of ERK1/2 protein (Fig. 3B) , suggesting that c-SRC is the upstream molecule of ERK1/2. Moreover, pre-treatment with PP2 or the ERK inhibitor (U0126, 5 μ M) prevented FA-induced increases in the levels of TP53, CDKN1A, and CDKN1B protein in COLO-205 (Fig. 3C) . Pre-treatment with U0126 also prevented FA-induced increases in the level of phosphoryated NF-kappa-B inhibitor alpha (p-Iκ Bα ) protein ( Fig. 4A ) and nuclear translocation of NFκ B and p-NFκ B (Fig. 4B) . We also examined whether nuclear translocation of NFκ B, which has been implicated in regulating the expression of TP53 in HUVEC 19 , is involved in the FA-induced up-regulation of TP53. As shown in Fig. 4C , pre-treatment with the NFκ B inhibitor, CAPE (5 μ M), prevented FA-induced increases in the levels of TP53, CDKN1A and CDKN1B protein in COLO-205. Moreover, FA treatment increased the binding of NFκ B (p65) onto the TP53 promoter (Fig. 4D ). These data suggest that activation of the c-SRC/ERK1/2/NFκ B-mediated pathway was involved in FA-induced increases in the levels of TP53, CDKN1A and CDKN1B protein. . In the present study, we examined which isoforms of FR were expressed in COLO-205. As shown in Fig. 5A , only the FRα isoform was detected in COLO-205. We next examined whether activation of FRα is involved in the FA-induced c-SRC activation. As illustrated in Fig. 5B , knock-down of FRα abolished the FA-induced activation in c-SRC, suggesting that FRα is involved in the FA-induced c-SRC activation. We also examined whether knock-down of FRα could abolish FA-induced increases in the levels of TP53, CDKN1A and CDKN1B protein. As shown in Fig. 5C , knock-down of FRα abolished FA-induced increases in the levels of TP53, CDKN1A, and CDKN1B protein.
FA causes tumor regression and prolongs the life span. Given the inhibition by FA of the growth of transformed colon cells in culture, we next determined whether administration of FA could affect the growth of tumors derived from human colon cancer cells in an in vivo setting. As illustrated in Fig. 6A ,B, intraperitoneal injection of FA (0-300 μ g) dose-dependently reduced the tumor volume. Moreover, the lifespan of FA-injected tumor bearing mice was lengthened as compared with the control mice injected with vehicle (Fig. 6C ). The degree of prolongation in lifespan was proportional to the dose of FA injected. Following upon the observation of cell cycle arrest and inhibition of angiogenesis, we examined the FA effect on the cell cycle and angiogenesis of the solid tumor derived from the implanted COLO-205. The levels of VWF protein, a marker of endothelial cells, were decreased and CDKN1A, CDKN1B and TP53 Effects of FA on the growth of HT-29 and LoVo colon cancer cell lines. To examine whether the FA-induced anti-growth effect was also observed in other colon cancer cell lines, the effect of FA on the growth of HT-29 (TP53 mutant) and LoVo (TP53 wild type) were studied. Initially, we examined which FR isoforms were expressed in HT-29 and LoVo. The RT-PCR analysis demonstrated that only the FRα isoform was detected in both HT-29 and LoVo (Fig. 7A ). As shown in Fig. 7B , daily treatment with FA for 4 days reduced the growth of both HT-29 and LoVo. We also examined whether the key molecules involved in the FA-induced growth inhibition in COLO-205 are also affected by FA treatment in HT-29 and LoVo. As shown in Fig. 7C , treatment with FA for 2 min also increased the levels of p-c-SRC and p-ERK1/2 in HT-29. However, FA only increased the levels of p-c-SRC and p-ERK2, but not p-ERK1, in LoVo. The effects of FA on the levels of CDKN1A, CDKN1B and TP53 protein were also examined. Since the S phase of the cell cycle of HT-29 and LoVo began at 8 h and 18 h after challenged with serum, respectively 20, 21 , we examined the changes of the levels of CDKN1A, CDKN1B and TP53 protein at 8 and 10 h (for HT-29) as well as 18 and 20 h (for LoVo) after FA treatment. As illustrated in Fig. 7D , FA increased the levels of CDKN1A, CDKN1B and TP53 protein in HT-29 at 8 h after treatment. In the FA-treated LoVo, the increased levels of TP53 protein were observed at 18 h after treatment, whereas the increased levels of CDKN1A and CDKN1B were not observed until 20 h after treatment.
Discussion
Previously, we uncovered a completely novel role of FA for anti-angiogenesis and demonstrated that FA inhibits proliferation of vascular endothelial cells through activating the c-SRC/ERK 2/NFκ B/TP53 signaling pathway mediated by FRγ 17 . In the present study, we examined the anticancer activity of FA in colon cancer cell lines, COLO-205, HT-29, and LoVo. Our results indicated that treatment with FA reduced the growth of these colon cancer cell lines. Using the COLO-205 as the cell model for further studies, our data suggest that FA inhibited proliferation of COLO-205 through activating the c-SRC/ ERK1/2/NFκ B/TP53 signaling pathway mediated by FRα and FA nutritional supplementation inhibited COLO-205 colon tumor growth and prolonged the life span of tumor bearing mice.
The FA-induced growth inhibition in COLO-205 is reversible when the cells are transferred to FA free culture media (data not shown). This finding is of considerable relevance because it is generally believed that FA is essential for the synthesis of adenine and thymidine, two of the four nucleic acids Figure 4A -B. Values (means ± s.e.mean.) shown in parentheses represent the relative protein abundance, which has been normalized with corresponding total protein or G3PDH and expressed as fold of its own control. Three samples were analyzed in each group. * p < 0.05 different from its own control. AS, antisense oligonucleotide; Co, control; Sc, scramble oligonucleotide; W, water.
that make up genes, DNA, and chromosomes. Previously, we demonstrated that the FA-induced inhibition of DNA synthesis in HUVEC is through increasing CDKN1A and CDKN1B expression, which in turn inhibits the CDK2 activity, and finally impairs the transition from the G1 to the S phase 17 . In the present study, we showed that FA increased the levels of TP53, CDKN1A and CDKN1B protein (Fig. 1C,D) . Knock-down of TP53 expression prevented FA-induced increases in the levels of CDKN1A and CDKN1B protein ( Fig. 2A) and the G0/G1 arrest (Fig. 2B) in COLO-205, suggesting that FA inhibited COLO-205 proliferation through a TP53-dependent pathway.
While CDKN1A is a known direct target of TP53, the regulation of CDKN1B expression by TP53 is not well established. Previously, we demonstrated that progesterone induces up-regulations in CDKN1B in HUVEC through a TP53-dependent pathway 22 . This conclusion was based on the evidences including that (1) transfection of HUVEC with dominant negative TP53 prevents progesterone-induced increases in the CDKN1B promoter activity and the level of CDKN1B protein; (2) treatment of HUVEC with TP53 siRNA prevents progesterone-induced increases in the level of CDKN1B protein; and (3) progesterone increases the TP53 DNA binding activity on the CDKN1B promoter in HUVEC. A similar phenomenon was also found in the FA-treated HUVEC 17 . The exact molecular mechanism underlying TP53-induced up-regulations in CDKN1B still deserves further investigation.
In the present study, we demonstrated a very narrow window of time for increases in the levels of TP53, CDKN1A and CDKN1B protein. Actually, a similar finding was also observed in the progesterone-induced up-regulations in TP53, CDKN1A and CDKN1B protein in HUVEC 22 . For such a narrow window of time for increases in the levels of TP53, CDKN1A and CDKN1B protein, one possible explanation is a sudden increase in the rate of its degradation. It has been indicated that the half-life of TP53 is primarily regulated by mouse double minute (MDM2), an important negative regulator of TP53. MDM2 targets to ubiquitin residues of TP53 and causes TP53 ubiquitination and proteasomal degradation. MDM2 is one of the TP53's target genes and any increase of TP53 usually leads to an increase in Mdm2 levels 23, 24 . We previously demonstrated that progesterone increases the level of MDM2 protein in HUVEC via an up-regulation of TP53 19 . The FA-induced increases in MDM2 were also observed in the FA-treated COLO-205 (Suppl. Fig. 6A ). In fact, rapid reductions of the intracellular CDKN1B protein to an undetectable level within 60 min during the progression from the G1 to the S phase through ubiquitin-mediated degradation and proteolytic processing was demonstrated 25 . However, when the cell had a longer exposure to FA treatment the levels of TP53, CDKN1A and CDKN1B protein will be increased again after the MDM2 is degraded. To test this hypothesis, we examined the levels of TP53, CDKN1A and CDKN1B protein in COLO-205 treated with FA for longer periods of time. Indeed, the increased levels of TP53, CDKN1A and CDKN1B protein were observed in the COLO-205 after four days continuous treatment with FA (Suppl. Fig. 6B ).
Four FR isoforms including FRα , FRβ , FRγ , and FRδ have been identified. The FRα and FRβ are attached to the membrane by a glycosylphosphatidylinositol (GPI) anchor 26, 27 . FRα is used as a highly selective tumor marker and may be targeted for the delivery of therapeutic compounds to tumor cells by coupling to derivatives of FA 28 . FRβ is expressed in malignant tissues of epithelial and non-epithelial origin, but not in established cell lines of the same origin 29 . FRγ is expressed in tissues of hematopoietic origin, such as spleen, thymus and bone marrow 30 . The expression pattern of FRδ suggests that it is highly restricted both spatially and temporally 31 . Previously, we identified the expression of FRγ in HUVEC, and demonstrated that FA inhibits HUVEC proliferation through activating the FRγ . In the present study, only FRα mRNA was detected in COLO-205 (Fig. 5A) . Knock-down of FRα by antisense oligonucleotide abolished the FA-induced activation of c-SRC (Fig. 5B) and increases in TP53, CDKN1A and CDKN1B protein (Fig. 5C) . Moreover, blockade of the activity of c-SRC, ERK1/2, or NFκ B prevented FA-induced increases in TP53, CDKN1A and CDKN1B protein. Taken together, these (Fig. 1A,B) . Second, FA might inhibit tumor angiogenesis and the associated tumor growth. Our previous studies demonstrated that FA inhibits the proliferation of cultured vascular endothelial cells in vitro and reduces the angiogenesis in vivo 17 . In the present study, we found that a lower level of VWF protein, a marker of vascular endothelial cells, was observed in the tumor isolated from the FA-treated mice as compared with those isolated from the vehicle-treated mice (Fig. 6A) , suggesting that tumor angiogenesis was reduced in FA-treated mice. To our knowledge, this is the first demonstration that FA inhibits COLO-205 colon cancer growth through inhibiting cancer cell proliferation and angiogenesis.
In the present study, we demonstrate that FA inhibits the progress of COLO-205 both in vitro and in vivo. The dosage used for in vivo study of FA-induced anti-tumor growth study is 100 to 300 μ g (i.p. daily), equivalent to 0.3 to 1 mg/kg/day, and was not cytotoxic for the vital organs. Epidemiologic studies have demonstrated that periconceptional dietary supplement of 0.4 to 5 mg FA per day significantly reduces occurrence and recurrence risks for infant neural tube defects without apparent side effects 32 .
In conclusion, the results from the present and our previous studies suggest that FA inhibits COLO-205 colon cancer growth through anti-cancer cell proliferation and anti-angiogenesis. FA induced cell cycle arrest in COLO-205 through up-regulating the expressions of CDKN1A and CDKN1B mediated by activation of the FRα /c-SRC/ERK1/2/NFκ B/TP53 signaling pathway. Although we have not completely finished the delineation of the signaling pathways involved in regulating FA-induced growth inhibitions in HT-29 and LoVo colon cancer cell lines, our preliminary data showed that FRα is the only isoform detected in HT-29 and LoVo and c-SRC as well as ERK were activated and the levels of TP53, CDKN1A and CDKN1B protein were increased in the FA-treated HT-29 and LoVo. These findings suggest that FA inhibited the growth of these colon cancer cells through a similar signaling pathway. The findings from the present in vitro and in vivo studies strongly suggest the potential applications of FA in the treatment of colon cancer.
Methods
Chemicals. FA, anti-vonWillebrand factor (VWF) antibody and anti-CDKN1B antibody were purchased from Sigma-Aldrich (St.Louis, MO). Trypsin-EDTA and kanamycin were purchased from Life Technologies (Grand Island, NY). Antibodies specific for G3PDH was purchased from GeneTex, Inc. (Hsinchu, Taiwan). Anti-TP53, p-ERK, ERK, Iκ Bα , NFκ B, and FR antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies specific for CDKN1A, p-Iκ Bα and p-NFκ B was purchased from Cell Signaling Technology, Inc. (Beverly, MA). c-SRC and p-c-SRC antibodies were purchased from Abcam (Cambridge, UK). PP2 was purchased from A. G. Scientific, Inc. (San Diego, CA). U0126 and caffeic acid phenethyl ester (CAPE) were purchased from Cayman Chemical (Ann Arbor, MI). MDM2 was purchased from Millipore (Temecula, CA).
Cell culture and Cell transfection. , HT-29 and LoVo purchased from ATCC were used in this study. These cells have performed STR-PCR profile at MB Mission Biotech. The cell was grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and kanamycine (100 ng/mL) in a humidified incubator (37 °C, 5% CO2). For transient transfection of the indicated constructs into COLO-205, jetPEI-HUVEC transfection reagent (Polyplus Transfection, Bioparc, France) was used and the transfection was performed according to the manufacturer's protocol. Briefly, jetPEI-COLO-205/DNA mixture was added drop-wise into the DMEM+ GlutamaxTM I medium (GIBCO) containing 2% FBS, mixed gently, and incubated in a humidified 37 °C incubator for 4 h. The growth medium was then replaced and the cell was incubated for the next 24 h.
[3H]thymidine incorporation. The [3H]thymidine (Amersham Biosciences, UK) incorporation was performed as previously described 33 . Briefly, COLO-205 were applied to 24-well plates in growth medium (RPMI-1640 supplemented with 10% FBS, 100 ng/mL kanamycine). After COLO-205 had grown to 60-70% confluence, they were rendered quiescent by incubation for 24 h in RPMI-1640 containing 0.04% FBS. RPMI-1640 supplemented with 10% FBS and PBS with or without FA (0.1-10 μ M) was added to the cell and the culture was allowed to incubate for 24 h. During the last 3 h of the incubation, [3H] thymidine was added at 1 μ Ci mL −1 (1 μ Ci = 37 kBq). Incorporated [3H]thymidine was extracted in 0.2 N NaOH and measured in a liquid scintillation counter.
Flow cytometric analysis.
The cell was transfected with pcDNA 3.1(+ ) or dominant-negative TP53 (DN-TP53) construct (2.5 μ g) for 5 h, rendered quiescent with serum free medium for 24 h, and then challenged with RPMI-1640 medium containing 10% FBS and PBS (control) or FA (10 μ M). Cells were harvested at various time points after released with trypsin-EDTA, washed with PBS, and fixed in 70% ethanol at 4 °C for 1 h. Ethanol was removed and cell pellet was washed with PBS twice before staining. DNA content of nuclei was determined by staining nuclear DNA with a solution containing propidium Scientific RepoRts | 5:11187 | DOi: 10.1038/srep11187 iodine (2 mg/mL) and DNase-free RNase A (10 mg/mL) and measured using a fluorescence-activated cell sorter.
Dominant-negative TP53 construct.
To amplification of the mutant (V143A) of TP53 18, 34 , recombinant PCR was performed. Synthesized cDNA (SuperScript III First-Strand Synthesis System for RT-PCR; Invitrogen, Carlsbad, CA) from HUVEC was used as a template and Phusion high-fidelity DNA polymerase (Finnzymes Diagnostics, Finland) with 3' to 5' exonuclease activity was used in subsequent PCR. Forward primer 5'-ATGGAGGAGCCGAGTCAG and reverse 5'-TCAGTCTGAGTCAGGCCCTTC primers were used for amplified full-length wild type TP53 (WT-TP53); then used two primer sets 1 and 2 (Table 1 ) were used to synthesize fragment A and fragment B. For each fragment, the amplified PCR product was purified and used as a mixed template for synthesizing TP53 V143A in the PCR reaction. The synthesized PCR product of TP53 V143A was purified, digested with restriction enzyme HindIII and EcoRV, and cloned into pcDNA 3.1(+ ) (Invitrogen). The TP53 V143A sequence fidelity was confirmed by ABI PRISM 377 DNA Analysis System. Trypan blue assay. As a measurement of cell viability, the cell was seeded onto 12 well dish and grown in RPMI-1640 medium containing 10% FBS. Media without (control) or with FA (10 μ M) were changed daily until cell counting and were released with trypsin-EDTA (GIBCO). The cell suspension was mixed with equal volume of 0.4% trypan blue solution (Sigma-Aldrich) and incubated at room temperature for 3 min. Cells were counted using the dual-chamber hemocytometer under microscope. Viable or nonviable cells were recorded from three independent counts for analysis.
MTT assay.
Protein extraction and Western blot analysis. The cell was seeded onto 6 cm dishes and grown in RPMI-1640 supplemented with 10% FBS. After cells had grown to subconfluence, they were rendered quiescent by incubation for 24 h in RPMI-1640 medium containing 0.04% FBS. The cell was released from quiescence with culture medium containing 10% FBS, treated with FA at indicated concentrations or PBS for the control group, washed with PBS, and then lysed in lysis buffer (0.5 M Tris-HCl, pH 6.8, and 0.4% sodium dodecyl sulfate). Western blot analyses were applied to determine the protein levels in cells; the electrophoresis was performed using 8% or 12% sodium dodecyl sulfate-polyacrylamide gel (3 h, 70 V). Separated proteins were transferred onto polyvinyl difluoride membranes (4 h, 400 mA), treated with 5% skim milk (Anchor, Auckland, NZ) to block the nonspecific IgGs and incubated overnight at 4 °C with specific antibody. The blot was then incubated with anti-mouse or anti-rabbit IgG (Jackson ImmunoResearch Laboratories) conjugated to horseradish peroxidase for 1 h. Subsequently, Table 1 . Primer sequences and amplicon size used in this study.
the polyvinyl difluoride membrane was developed with chemiluminescence reagent (PerkinElmer Life Sciences, Boston, MA). The intensity of each band was quantified by densitometry analysis using Image Pro Plus 4.5 software. In each figure, the gels have been run under the same experimental conditions and cropped blots were shown. The methods were carried out in "accordance" with the approved guidelines.
Reverse Transcription-PCR (RT-PCR).
Total cellular RNA was extracted from cells with Trizol (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol 22 . The RNA pellet was washed with 75% cold ethanol, air dried, and re-dissolved in 20 μ L diethyl pyrocarbonate-treated water. Two μ g of total RNA were used in a total of 20 μ L reaction volume as a template for PCR amplification. PCR was done under standard conditions in 20 μ L of 10 mM Tris (pH 8.3), 40 mM KCl, 1.5 mM MgCl 2 , 250 μ mol/L dNTP, 10 μ M of each primer (sense and antisense), and 1 unit Taq DNA polymerase. The PCR primer sequences for FRα , FRβ , FRγ , and FRδ were listed in Table 1 . The PCR products were electrophoresed on a 1.5% agarose in 0.5X Tris-acetate/EDTA buffer and stained with ethidium bromide solution (Roche, Mannheim, Germany).
Antisense oligonucleotide. The antisense oligonucleotide (AS) sequence of FRα :
5'-TGTTGTCATCCGCTGAGCCAT-3' was designed by previous study 35 , which is complementary to the region of the sense template of FRα . The scramble oligonucleotide (Sc) sequence of FRα : 5'-GTCTCGTTCGTATACGCTACG-3' was used for the control. Briefly, cells were plated per well in 6 cm plate and washed twice with serum-free MEM. AS or Sc was added in RPMI-1640 containing 5% FBS without antibiotic, and the final concentration of oligonucleotide was 10 μ M each. Cells were incubated with AS or Sc for 4 h. Transfections were terminated by the addition of RPMI-1640 containing 10% FBS.
Chromatin immunoprecipitation (ChIP) assay. The ChIP assay was performed as previously described 19 . Briefly, COLO-205 was fixed with 1% formaldehyde in room temperature for 10 min, and then stopped by glycine (final concentration of 0.125 M). The cell was washed twice with ice-cold PBS, resuspended, and then homogenized in 0.5 mL swelling buffer (5 mM 1,4-piperazine diethane sulfonic acid, pH 8.0; 0.5% Triton X-100; 0.5 mM protease inhibitor (G-Biosciences, LA, USA)). The nuclei pellet was sonicated in 0.5 mL sonication buffer (10 mM EDTA; 50 mM Tris-HCl, pH 8.0; 0.5 mM PMSF) plus protease inhibitor (G-Biosciences). A solution containing 0.1% SDS and 85 mM KCl was added to reduce the nonspecific binding. Samples were divided into two equal amounts and individually incubated for 1 h at 4 °C with 1.5 μ g of anti-NFκ B antibody (Santa Cruz Biotechnology) or 1.5 μ g of normal mouse IgG (Santa Cruz Biotechnology) as a negative control, added with 30 uL of protein A agarose/salmon sperm DNA slurry (Upstate, Temecula, CA), and then incubated at 4 °C overnight with constant rotation. The protein A agarose/antibody/chromatin complex was washed and then dissociated using the Upstate ChIP protocol. DNA was purified using the Geneaid PCR purification kit (Geneaid, Taipei, Taiwan) and eluted in a 50 μ L elution buffer (10 mM Tris-HCl pH 8.5). Two μ L of the DNA was assayed in a PCR cycle. The NFκ B binding site within the TP53 promoter was analyzed in MOTIF Search (http://motif.genome. jp/) and the primers designed using Primer-BLAST of National Center for Biotechnology Information (Bethesda, MD) were listed in Table 1 . All the PCR products were analyzed using 2% agarose gels containing ethidium bromide (New Taipei city, Taiwan).
Nuclear extraction.
To examine the effect of FA on nuclear translocation of NFκ B, the NE-PER® nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific, Rockford, IL) were used and the extraction was performed according to the manufacturer's protocol. Briefly, the cell pellet was disrupted in cytoplasmic extraction reagent I buffer plus protease inhibitor (G-Biosciences), and then lysed in cytoplasmic extraction reagent II buffer to release cytoplasmic proteins. After being centrifuged at 13,000 rpm for 10 min at 4 °C, the insoluble pellet, which contained nuclear proteins, was washed with ice-cold PBS twice, and then incubated in nuclear extraction reagent buffer plus protease inhibitor (G-Biosciences).
Tumor growth assay. The tumor growth assay was performed as previously described 36 . The COLO-205 cells were implanted by injection of a tumor suspension (3 × 10 6 cells in 0.1 mL RPMI 1640) subcutaneously in the flanks of male severe combined immunodeficiency (SCID) mice (BALB/c-nu, National Animal Center, Taiwan). Each mouse was implanted with one bolus of tumor cells on day 7. Dosing (i.p.) with FA was begun 7 days after implantation (day 0), when the tumors reach ~7 mm 3 in volume. Either the vehicle or FA at a dose of 100 μ g or 300 μ g was given i.p. daily. All in vivo procedures were approved by the Taipei Medical University Animal Care and Use Committee.
Statistical analysis.
Values represent the means ± s.e.mean. Three to four samples were analyzed in each experiment. Comparisons were subjected to t-test and one way analysis of variance (ANOVA) followed by Fisher's least significant difference test. Significance was accepted at P < 0.05
